AzTrials
AzTrials

Type 1 DiabetesNCT00793741

Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness

An observational study of Type 1 Diabetes and Hypoglycemia Unawareness, run by University of Minnesota at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether islet transplantation alters brain glucose concentrations in patients with type 1 diabetes, recurrent hypoglycemia, and hypoglycemia unawareness when compared to that measured prior to transplant in the same subjects. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Type 1 Diabetes, Hypoglycemia Unawareness
What is being tested?
somatostatin
How many people
19 participants
Where
1 siteUnited States
Study dates
Dec 2007to Mar 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Endocrinology clinic, community

Who may be able to join

  • Age 18-65
  • Must be able to provide informed consent
  • Type 1 diabetes >5 years duration
  • Healthy controls

Who cannot join

  • Over 300 pounds
  • Claustrophobic
  • History of ischemic heart disease, arrhythmia or seizure disorder
  • Pregnant
  • On medications known to alter blood flow or carbohydrate metabolism
  • Have internally located pieces of metal

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Minnesota

    Minneapolis, Minnesota, 55455

Other trials in United States

About this study

The purpose of this study is to determine whether islet transplantation alters brain glucose concentrations in patients with type 1 diabetes, recurrent hypoglycemia, and hypoglycemia unawareness when compared to that measured prior to transplant in the same subjects.

Read the detailed description

Individuals with type 1 diabetes and hypoglycemia unawareness who become active islet transplant candidates and matched controls will be recruited for participation in this study. Subjects will undergo a hyperglycemic clamp with somatostatin before and 6 months after islet transplantation. During the clamp study, their brain glucose concentrations will be measured by proton magnetic resonance spectroscopy. Following these measurements, subjects will undergo a hypoglycemic clamp study to assess their counterregulatory response.

On the morning of the study subjects will report to the Clinical Research Center in the CMRR and be asked to do the following:

  1. All subjects will be asked not to eat anything after midnight on the day before the magnet study at the Magnet Center. A small plastic catheter will be placed in a vein in each arm for infusion of hormones. A third plastic catheter will be placed in a foot vein for measuring blood glucose levels. The foot and distal leg will be placed in a heated blanket for the duration of the study to speed up the flow of blood through the vein and for easy withdrawing of blood. During the study subjects will receive carefully calculated doses of insulin, glucose, potassium phosphate, and somatostatin. These substances will be contained in syringes or bags and pumped through intravenous catheters placed in the arms. Insulin and somatostatin are hormones that are made naturally by the body. Initially we will keep blood sugar at the normal level. The blood glucose will then be raised by infusing glucose at a calculated rate. We will maintain the high blood sugar concentration for 45 to 120 minutes. This causes no symptoms other than a necessity f to pass urine more frequently than normal. The blood glucose infusion will then be dropped to allow blood glucose to drop in small steps to the normal glucose concentration. We will draw at most 15 oz. of blood during this part of the study.
  2. All subjects will be asked to participate in a second experiment after the magnet study. Subjects may chose to perform this part of the study at Yale University. If subjects choose to stay at the University Of Minnesota, they will be participating in the second experiment either the same day or the day after the first experiment. If done the same day, the arm catheters will be left in place for infusion of insulin, potassium phosphate, and glucose. A third catheter may be placed in the hand for venous blood sampling. This hand will be placed in a warming box to ensure adequate blood flow and accurate laboratory results. Blood will be drawn every 5 minutes for measurement of glucose and other hormones. The total amount of blood drawn will be about 10 tablespoons. Insulin will be infused to lower blood sugar level to a level below the normal range. It will be maintained at this low level for thirty minutes after which time the insulin infusion will be discontinued and the blood sugar level allowed to normalize. Subjects will then be given a meal.
  3. Subjects with type 1 diabetes will be asked to spend the night before each study at the General Clinical Research Center so that blood glucose values can be maintained between 80-110 mg/dl. They will be asked to hold insulin doses in the evening before and on the morning of the study and insulin will be provided via an intravenous infusion. For those subjects with diabetes who chose to undergo all testing at the University of Minnesota, they will be followed as inpatients in the GCRC during one to two days of testing.
  4. Following islet transplant subjects will be asked to undergo the magnet study described under point #1 above and the hypoglycemia study described under point #3 above at approximately 3-9 months after the procedure.
Being tested
somatostatin
Keywords
Type 1 diabetes, Hypoglycemia unawareness, Islet transplant
Medical subject headings
Diabetes Mellitus, Type 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • somatostatinDrug

    Somatostatin may be used to suppress endogenous insulin secretion

Study groups in NCT00793741
Study groupRoleWhat they receive
1Type 1 Diabetes Hypoglycemia unawareness Islet transplant candidate
Receives: Drug: somatostatin
2Healthy control subjects
Receives: Drug: somatostatin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Brain glucose concentration as measured by NMR spectroscopy

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Nov 2008 (estimated)
  2. Study startDec 2007
  3. Primary completionMar 2017
  4. Study completionMar 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
19 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00793741
Sponsor's protocol ID
9711M00055
Status last verified
Jan 2018
First submitted
18 Nov 2008
Last updated
18 Jan 2018
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Type 1 Diabetes and Hypoglycemia Unawareness, run by University of Minnesota at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Brain glucose concentration as measured by NMR spectroscopy (time frame: 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in